Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

Nitin Jain, Jorge Cortes, Alfonso Quintás-Cardama, Taghi Manshouri, Raja Luthra, Guillermo Garcia-Manero, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status'. Together they form a unique fingerprint.

Medicine & Life Sciences